OSPEDALE POLICLINICO G.B. ROSSI Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT02076594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ospedale Borgo Trento - Verona | OSPEDALE POLICLINICO G.B. ROSSI (BORGO ROMA) DI VERONA

Active Ingredients

Drugs in Phase 4 Trials (2)

hypromelloses (1 trial)

ozonated oil (1 trial)

Drugs in Phase 3 Trials (4)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

epirubicin (ellence) (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 4)

Eye Infections (Phase 4)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 6